Provided by Tiger Trade Technology Pte. Ltd.

OS Therapies

1.68
-0.1400-7.69%
Post-market: 1.680.00000.00%19:59 EDT
Volume:825.87K
Turnover:1.41M
Market Cap:78.07M
PE:-1.60
High:1.84
Open:1.81
Low:1.66
Close:1.82
52wk High:2.32
52wk Low:1.15
Shares:46.47M
Float Shares:33.71M
Volume Ratio:0.90
T/O Rate:2.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0524
EPS(LYR):-0.9829
ROE:-914.04%
ROA:-232.65%
PB:-6.55
PE(LYR):-1.71

Loading ...

OS Therapies Announces Prospectus for Secondary Share Resales

TIPRANKS
·
Yesterday

OS Therapies Files Prospectus for Resale of up to 5,874,094 Shares by Selling Stockholders

Reuters
·
Yesterday

OS Therapies Stockholders Approve Incentive Plan and Board

TIPRANKS
·
Sep 10

OS Therapies Shareholders Approve Amended 2023 Incentive Compensation Plan at Annual Meeting

Reuters
·
Sep 10

Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and SailPoint, Inc. (SAIL)

TIPRANKS
·
Sep 10

Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON)

TIPRANKS
·
Sep 08

OS Therapies Reports 71.2% 3-Year Survival in Phase 2b OST-HER2 Metastatic Osteosarcoma Trial

Reuters
·
Sep 08

OS Therapies Management to Attend H.C. Wainwright Global Investment Conference

Reuters
·
Sep 02

OS Therapies Launches $75 Million At-The-Market Offering

TIPRANKS
·
Aug 22

OS Therapies Launches USD 75 Million At-the-Market Equity Offering Via Jefferies

Reuters
·
Aug 22

Os Therapies - Enters Open Market Sale Agreement with Jefferies - SEC Filing

THOMSON REUTERS
·
Aug 22

Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Nicola Mining Inc. Unsponsored ADR (NICM)

TIPRANKS
·
Aug 18

OS Therapies Net Loss Widens to $19.03 Million in FY26 First Half; Revenue Remains no Revenue

Reuters
·
Aug 15

OS Therapies Wins FDA Type C Meeting to Review 2.5-Year Survival Data for OST-HER2 Phase 2b Osteosarcoma Trial

Reuters
·
Aug 13

OS Therapies Announces Convertible Note Financing and Warrants

TIPRANKS
·
Aug 13

Os Therapies - to Issue Senior Secured Convertible Notes up to $10 Mln in Private Placement - SEC Filing

THOMSON REUTERS
·
Aug 13

Os Therapies - Co & Its Wholly Owned Subsidiaries Entered Securities Purchase Agreement on August 10, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 13

OS Therapies Prices up to $10 Million Senior Secured Convertible Note Private Placement

Reuters
·
Aug 13

OS Therapies Agrees to Repay Leonite Debt in USD 1.9 Million Cash Settlement

Reuters
·
Aug 07

OS Therapies - Terminates at Market Issuance Sales Agreement on July 23, 2026 - SEC Filing

Reuters
·
Jul 30